The changing face of Clostridium difficile: what treatment options remain?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 18042108.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In this issue of the Journal, an article by Pepin et al. documents the shifting sands of the modern-day Clostridium difficile epidemic as seen in Quebec. Pepin and coauthors' observation that the superior activity of vancomycin over metronidazole has been lost since the emergence there of the hypervirulent strain NAP1/027 in 2003 has implications for the future treatment of C. difficile-associated diarrhea (CDAD). This editorial explores these, particularly in complicated cases and high-risk populations.
Medical subject headings
- Anti-Bacterial Agents
- Clostridioides difficile
- Enterocolitis, Pseudomembranous
- Metronidazole
- Vancomycin